For patients and healthcare providers in the United States, you can learn more about Oxbryta by visiting the product website or downloading the full U.S. prescribing information.
About GBT
GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.
Innovative Science
We are passionate and committed to developing new therapies that can provide transformative clinical benefit to patients.